Fig. 4
In vivo therapeutic efficacy of PRV-LAV. A Timeline of the experimental setup for the experiments in the Balb/c nude or NOD-scid mouse model. B-G Tumor volume curves (B, D, F) and Kaplan–Meier survival curves (C, E, G) for mice bearing GBM, HepG2, and A549 tumors treated with vehicle or PRV-LAV (1 × 107 PFUs, intratumorally). H-I Therapeutic activity of PRV-LAV in the liver cancer PDX model (LIHC 00184006). Tumor volume curves (H) and Kaplan–Meier survival curves (I) for PDX mice treated with 4 doses of vehicle (n = 6) or PRV-LAV (n = 8) (1 × 107 PFUs, intratumorally). J Timeline of the experimental setup for the experiments in Hepa1-6 and CT26 syngeneic models in immunocompetent mice. K-N Changes in the injected (K, M) and distant (L, N) tumor volumes curves for mice bearing Hepa1-6 and CT26 tumors treated with vehicle or PRV-LAV (1 × 107 PFUs, intratumorally). In (B, D, F, H, K-N), comparisons were performed by AUC analysis. Statistical analysis was performed by t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Statistical analysis was performed using the log-rank test in (C, E, G, I). O Tumor cells were inoculated subcutaneously into the single hind-flank of mice. After 60 days post PRV-LAV treatment, cured mice treated with PRV-LAV were rechallenged with two-fold increased number of the same cancer cells. Recurrence rates were monitored in all groups